What Researchers Did
Researchers conducted a systematic review of 16 clinical trials examining HBOT efficacy for idiopathic sudden sensorineural hearing loss, analyzing whether HBOT provides benefit overall or in specific patient subgroups.
What They Found
In the overall group of sudden hearing loss patients, no statistically significant benefit of adding HBOT to steroid therapy was found. However, in patients with severe or profound hearing loss (initial threshold above 81 dB), HBOT combined with steroids showed a statistically significant treatment benefit (p = 0.005).
What This Means for Canadian Patients
This systematic review gives Canadian ENT specialists a clear clinical decision point: HBOT for sudden hearing loss is most justified when the initial hearing loss is severe or profound. For patients with milder loss, steroids alone may be sufficient, while HBOT should be prioritized for the most severely affected patients.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The 16 included studies varied widely in design, HBOT protocols, and outcome measures; heterogeneity limits the strength of pooled conclusions and subgroup analyses.